152 related articles for article (PubMed ID: 25060707)
1. HMGN2, a new anti-tumor effector molecule of CD8⁺ T cells.
Su L; Hu A; Luo Y; Zhou W; Zhang P; Feng Y
Mol Cancer; 2014 Jul; 13():178. PubMed ID: 25060707
[TBL] [Abstract][Full Text] [Related]
2. HMGN2: An Antitumor Effector Molecule of γδT Cells.
Chen J; Fan Y; Cui B; Li X; Yu Y; Du Y; Chen Q; Feng Y; Zhang P
J Immunother; 2018 Apr; 41(3):118-124. PubMed ID: 29401165
[TBL] [Abstract][Full Text] [Related]
3. HMGN2 protein inhibits the growth of infected T24 cells in vitro.
Wei D; Zhang P; Zhou M; Feng Y; Chen Q
J Cancer Res Ther; 2014; 10(2):299-304. PubMed ID: 25022381
[TBL] [Abstract][Full Text] [Related]
4. [Interleukin-12 restores and promotes the T-cell immune function inhibited by 5-fluorouracil].
Chi PD; Li L; Fan YY; Wu CY
Ai Zheng; 2007 Aug; 26(8):801-8. PubMed ID: 17697537
[TBL] [Abstract][Full Text] [Related]
5. Cardiotoxin-III selectively enhances activation-induced apoptosis of human CD8+ T lymphocytes.
Su SH; Su SJ; Lin SR; Chang KL
Toxicol Appl Pharmacol; 2003 Nov; 193(1):97-105. PubMed ID: 14613720
[TBL] [Abstract][Full Text] [Related]
6. Nucleosome-binding protein HMGN2 exhibits antitumor activity in oral squamous cell carcinoma.
Hu A; Dong X; Liu X; Zhang P; Zhang Y; Su N; Chen Q; Feng Y
Oncol Lett; 2014 Jan; 7(1):115-120. PubMed ID: 24348831
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effect of HMGN2 protein on human hepatitis B virus expression and replication in the HepG2.2.15 cell line.
Feng Y; He F; Zhang P; Wu Q; Huang N; Tang H; Kong X; Li Y; Lu J; Chen Q; Wang B
Antiviral Res; 2009 Mar; 81(3):277-82. PubMed ID: 19150374
[TBL] [Abstract][Full Text] [Related]
8. Recombinant jurkat cells (HMGN2-T cells) secrete cytokines and inhibit the growth of tumor cells.
Li H; Wu X; Bu D; Wang L; Xu X; Wang Y; Liu Y; Zhu P
J Mol Histol; 2022 Aug; 53(4):741-751. PubMed ID: 35861945
[TBL] [Abstract][Full Text] [Related]
9. Activated human NK and CD8+ T cells express both TNF-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors but are resistant to TRAIL-mediated cytotoxicity.
Mirandola P; Ponti C; Gobbi G; Sponzilli I; Vaccarezza M; Cocco L; Zauli G; Secchiero P; Manzoli FA; Vitale M
Blood; 2004 Oct; 104(8):2418-24. PubMed ID: 15205263
[TBL] [Abstract][Full Text] [Related]
10. [Modulation of TLR9 on anti-tumor immune responses of peripheral blood mononuclear cells from patients with non-small-cell lung cancer].
Ren T; Cai YY; Liang YJ; Jin ML; Guo ZL; Tao MF; He X
Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(17):1168-72. PubMed ID: 18844109
[TBL] [Abstract][Full Text] [Related]
11. [High Mobility Group Chromosal Protein N2 Is Expected to be as A Target of Cellular Immunetherapy in Leukemia and Tumors].
Li HH; Zhu P; Wu XQ; Liu YF; Wang LH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Aug; 23(4):915-8. PubMed ID: 26314417
[TBL] [Abstract][Full Text] [Related]
12. Induction of autologous tumor-specific cytotoxic T-lymphocyte activity against a human renal carcinoma cell line by B7-1 (CD8O) costimulation.
Wang YC; Zhu L; McHugh R; Graham SD; Hillyer CD; Dillehay D; Sell KW; Selvaraj P
J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):1-8. PubMed ID: 9147700
[TBL] [Abstract][Full Text] [Related]
13. Effector activity of decidual CD8+ T lymphocytes in early human pregnancy.
Scaife PJ; Bulmer JN; Robson SC; Innes BA; Searle RF
Biol Reprod; 2006 Oct; 75(4):562-7. PubMed ID: 16822900
[TBL] [Abstract][Full Text] [Related]
14. Lysis of fresh solid tumor targets in the presence of Con A is mediated primarily by Leu 7+ peripheral blood T lymphocytes: blocking by the anti-CD3 monoclonal antibody and comparison with recombinant interleukin 2-induced lysis by natural killer cells.
Itoh K; Platsoucas CD; Tilden AB; Pollock RE; Balch CM
Cell Immunol; 1987 Sep; 108(2):283-96. PubMed ID: 3113741
[TBL] [Abstract][Full Text] [Related]
15. Systematic comparison of dendritic cell-based immunotherapeutic strategies for malignant gliomas: in vitro induction of cytolytic and natural killer-like T cells.
Parajuli P; Mathupala S; Sloan AE
Neurosurgery; 2004 Nov; 55(5):1194-204. PubMed ID: 15509326
[TBL] [Abstract][Full Text] [Related]
16. Leu-Leu-OMe sensitivity of human activated killer cells: delineation of a distinct class of cytotoxic T lymphocytes capable of lysing tumor targets.
Thiele DL; Lipsky PE
J Immunol; 1986 Aug; 137(4):1399-406. PubMed ID: 3488348
[TBL] [Abstract][Full Text] [Related]
17. Role of cross-talk between IFN-alpha-induced monocyte-derived dendritic cells and NK cells in priming CD8+ T cell responses against human tumor antigens.
Tosi D; Valenti R; Cova A; Sovena G; Huber V; Pilla L; Arienti F; Belardelli F; Parmiani G; Rivoltini L
J Immunol; 2004 May; 172(9):5363-70. PubMed ID: 15100276
[TBL] [Abstract][Full Text] [Related]
18. Differential effect of sodium arsenite during the activation of human CD4+ and CD8+ T lymphocytes.
Tenorio EP; Saavedra R
Int Immunopharmacol; 2005 Dec; 5(13-14):1853-69. PubMed ID: 16275621
[TBL] [Abstract][Full Text] [Related]
19. [T lymphocytes with chimeric receptor induce carcinoembryonic antigen-positive specific gastric carcinoma cells apoptosis].
Xu HY; Xu L; Gao JH; Li KZ; Dou KF
Zhonghua Yi Xue Za Zhi; 2007 Apr; 87(15):1053-7. PubMed ID: 17672971
[TBL] [Abstract][Full Text] [Related]
20. Effect of IL-15 addition on asbestos-induced suppression of human cytotoxic T lymphocyte induction.
Kumagai-Takei N; Nishimura Y; Matsuzaki H; Lee S; Yoshitome K; Ito T; Otsuki T
Environ Health Prev Med; 2021 Apr; 26(1):50. PubMed ID: 33874885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
